Notice NOT-MH-19-031 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-318 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat Substance Use Disorders (SUDs) move through the drug development process. Both the project period and budget of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding. Project aims can range from the development of a new molecular entity to the expansion of an existing medications clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process. It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs.

Notice NOT-OD-19-125 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-052 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-051 from the NIH Guide for Grants and Contracts

Notice NOT-AG-19-031 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-126 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-050 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-053 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-064 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-123 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-20-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites projects focused on defining the factors that influence microbiome composition and functional characteristics during aging, understanding how the aging microbiome relates to the causes and pathophysiology of age-related chronic diseases, and development and testing of targeted interventions through diet, drugs, or live organisms. This FOA will accept basic mechanistic, preclinical studies in animal models and human studies leveraging existing human longitudinal cohorts.

Funding Opportunity RFA-AT-20-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a Center of Excellence for Natural Product Drug Interaction Research to provide leadership in the study of natural product drug interactions. The ultimate goals of this program are to 1) clearly establish the clinical relevance of pharmacokinetic interactions from a select number of natural products, and 2) provide guidance and leadership to the broader research community on how best to research metabolism mediated drug interactions involving complex natural products. The Center will 1) identify, prioritize, source and characterize three to five natural products with potential to exhibit clinically significant interactions with commonly used medications; 2) perform all necessary preclinical work to characterize the interaction potential of the natural products including identifying the key mediators of any pharmacokinetic interaction as well as the mechanism(s) and magnitude of that interaction; 3) if warranted based on preclinical work, conduct rigorously designed clinical studies of these natural products to provide definitive data regarding the magnitude of any interaction in humans; 4) develop and maintain a repository for the data and methodology resources generated by this project as well as data generated by other researchers (especially the R21 grants funded through the companion RFA AT-20-001) regarding pharmacokinetic interactions involving natural products; and 5) provide ongoing guidance and leadership to the relevant research communities regarding how best to conduct research on pharmacokinetic natural product drug interactions; thereby facilitating better design of future research and ultimately better decisions regarding the concomitant use of medications and natural products.

Funding Opportunity RFA-AT-20-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that seek to identify natural products with the potential to inhibit or induce Phase I and Phase II drug metabolizing enzymes and drug transporters, thereby possibly contributing to pharmacokinetic interactions with other medications. These in vitro studies may include screening libraries of complex extracts and/or purified natural products in suitable medium to high throughput assays to identify potential interactions. They may also include isolation and identification of novel, or not commercially available, natural products within complex mixtures that exhibit pharmacokinetic interactions. This FOA is part of a larger investment from NCCIH that includes a U54 Center of Excellence for Natural Product Drug Interaction Research. It is expected that data generated in projects supported under this FOA will be uploaded and made publicly available through the data repository maintained by the U54 Center.

Funding Opportunity RFA-AG-20-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites early-stage physicians and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. NIA is pursuing this initiative to recruit early-stage investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a PD/PI at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain.

Funding Opportunity RFA-AG-20-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. The National Institute on Aging (NIA) is pursuing this initiative to recruit early-stage investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a Program Director/Principal Investigator (PD/PI) at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain.

Funding Opportunity RFA-DK-19-007 from the NIH Guide for Grants and Contracts. This FOA invites new applications for the (Re)Building a Kidney (RBK) Consortium. The goal of the RBK is to improve or restore failing kidney function after injury or disease. This FOA invites teams of investigators with complementary expertise to develop and test novel ways to either (1) stimulate productive kidney repair/regeneration in vivo, or (2) generate functional kidney tissue ex vivo for transplantation.

Notice NOT-DA-19-059 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-063 from the NIH Guide for Grants and Contracts

Funding Opportunity PAS-19-317 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to NIA's Small Business Technology Transfer Research (STTR) program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.